ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and ...

Exidavnemab is a monoclonal antibody designed to eliminate aggregated clumps of the protein biomarker and slow progression of Parkinson's disease.

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to ...

Monday said Phase 3 TEMPO-2 study evaluating tavapadon in early Parkinson's disease met its primary goal. In the ...

We here at EdExec pride ourselves in creating solutions for suppliers to deliver their message in the most effective and ...

Explore the concept of Parkinson’s Law and learn how setting realistic deadlines can help you manage your tasks more ...